4//SEC Filing
Dhingra Ankur 4
Accession 0001599298-24-000046
CIK 0001599298other
Filed
Mar 26, 8:00 PM ET
Accepted
Mar 27, 8:27 PM ET
Size
5.8 KB
Accession
0001599298-24-000046
Insider Transaction Report
Form 4
Dhingra Ankur
Chief Financial Officer
Transactions
- Purchase
Common Stock
2024-03-26$3.75/sh+100,000$375,000→ 354,958 total(indirect: By Trust)
Footnotes (2)
- [F1]The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.74 to $3.76 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Documents
Issuer
Summit Therapeutics Inc.
CIK 0001599298
Entity typeother
Related Parties
1- filerCIK 0001849682
Filing Metadata
- Form type
- 4
- Filed
- Mar 26, 8:00 PM ET
- Accepted
- Mar 27, 8:27 PM ET
- Size
- 5.8 KB